Last updated: February 17, 2026
Overview
NDC 24385-0075 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody developed by Roche for the treatment of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). Introduced in 2017, Ocrevus has gained significant market share due to its efficacy in slowing disease progression.
Market Landscape
Indications and Usage:
Ocrevus targets relapsing-remitting MS (RRMS) and PPMS. Its approval in 2017 and subsequent labeling updates have expanded its indications, improving access across patient populations.
Competitive Positioning:
Key competitors include:
- Beta interferons (e.g., Avonex, Rebif)
- Glatiramer acetate (Copaxone)
- Tysabri (natalizumab) from Biogen
- Kesimpta (ofatumumab) from Novartis
- Lemtrada (alemtuzumab) from Sanofi/Regeneron
Ocrevus’s differentiated mechanism and dosing schedule (every six months) give it advantages over injectable therapies.
Market Size and Trends:
The MS treatment market globally was valued at approximately $20 billion in 2022, projected to grow at a CAGR of 6% through 2030. North America accounts for roughly 60% of sales, driven by high diagnosis rates and reimbursement access.
Prescription Trends:
- Steady increase in Ocrevus prescriptions across US, Europe, and Asia.
- Growth driven by expanded indications, increasing prevalence, and patient preference for less frequent dosing.
- Market penetration remains high among biologic MS treatments, though competition intensifies with new entrants like Kesimpta and longer-acting formulations.
Pricing Analysis
Current List Price:
- The average wholesale price (AWP) for Ocrevus per 300 mg vial is approximately $6,800 (reflecting 600 mg dose typical for a two-injection cycle).
- Typical treatment involves an initial infusion of 600 mg followed by maintenance doses every 6 months, with annual costs roughly $13,600 - $15,000 per patient.
| Pricing Compared to Competitors: |
Drug |
Dosing Schedule |
Approximate Annual Cost |
Notes |
| Ocrevus (ocrelizumab) |
600 mg every 6 months |
$13,600 - $15,000 |
Biologic, high efficacy in progressive MS |
| Tysabri (natalizumab) |
300 mg monthly |
~$78,000 |
High efficacy but associated with PML risk |
| Gilenya (fingolimod) |
Daily oral |
~$70,000 |
Oral route, less efficacy in progressive MS |
| Kesimpta (ofatumumab) |
Monthly subcutaneous injections |
~$50,000 |
Recent entry, competitive pricing, convenience |
Price Projection Factors
Regulatory & Reimbursement Changes:
- Price adjustments linked to policy shifts, including drug price negotiations facilitated by agencies like Medicare and private payers.
- The US Inflation Reduction Act (2022) impacts drug pricing and rebates, likely driving future price stabilization or reduction in negotiated markets.
Market Dynamics:
- Biosimilars are not yet available due to Roche’s patent exclusivity; patent expiry expected around 2028-2030.
- Biosimilar entries in subsequent years could pressure price reductions.
- Entry of newer therapies with similar efficacy but lower costs could reduce Ocrevus's market share, impacting unit prices.
Pricing Trends:
- Historically, biologics see initial high launch prices with gradual reductions over time.
- Price erosion is typically modest for high-value MS biologics due to limited biosimilar competition in the short term.
| Projected Price Range (Next 2-5 Years): |
Year |
Unit Price (per 300 mg vial) |
Key Assumptions |
| 2023 |
$6,800 |
Current level, with minor annual inflation (~2%) |
| 2024 |
$6,900 - $7,000 |
Slight price increase, market stabilization |
| 2025 |
$6,800 - $6,900 |
Potential price pressure from biosimilars, policy changes |
| 2026+ |
$6,500 - $7,000 |
Possible price reductions if biosimilars launched, increased competition |
Implications for Stakeholders
- Manufacturers and investors should monitor patent expiration timelines and biosimilar development.
- Payers and providers need to prepare for potential price negotiations and formulary shifts.
- Roche’s continued investing in clinical trials for expanded indications may sustain demand regardless of price pressures.
Key Takeaways
- The MS biologic market remains surge-prone, with Ocrevus commanding premium pricing due to high efficacy and dosing convenience.
- Price stability is expected in the near-term, with gradual erosion possible from biosimilar entrants post-2028.
- Market growth will depend on expanded indications, payer policies, and competitive landscape shifts.
FAQs
1. What factors most influence Ocrevus’s pricing?
The primary factors are manufacturing costs, market competition, reimbursement policies, and patent status. Biosimilar entry post-2028 could lead to price reductions.
2. How does Ocrevus compare to newer MS therapies in cost?
Ocrevus costs roughly $13,600 to $15,000 annually, higher than oral therapies like Gilenya but lower than drugs such as Tysabri. Its dosing schedule reduces administration costs, balancing its premium price.
3. Are biosimilars expected to significantly reduce Ocrevus prices?
Yes. Biosimilar competition, likely after patent expiration around 2028-2030, could decrease prices by 20-40%, depending on market dynamics.
4. How do reimbursement policies affect Ocrevus’s market prices?
Reimbursement negotiations can lead to discounts or formulary restrictions, influencing the effective price paid by payers and patients.
5. What is the outlook for Ocrevus’s market share?
Market share is expected to stabilize or grow modestly due to its efficacy. However, competition from new entrants like Kesimpta and generics post-2028 could cause shifts.
Sources
- Roche. Ocrevus prescribing information.
- IMS Health. MS market analysis 2022.
- IQVIA. Global biologics market forecast.
- US FDA. Drug patent and exclusivity timeline.
- CMS. Inflation Reduction Act impact on drug pricing.
